Victoza Market

The global Victoza market is estimated to be valued at USD 647.3 Mn in 2025 and is expected to decline to USD 172.6 Mn by 2032, exhibiting a compound annual growth rate (CAGR) of -17.2% from 2025 to 2032.

The global Victoza market, a key segment within the pharmaceutical industry, focuses on managing type 2 diabetes mellitus with Victoza (liraglutide), a glucagon-like peptide-1 (GLP-1) receptor agonist developed by Novo Nordisk. Initially, the drug gained significant traction due to its efficacy in glycemic control and potential cardiovascular benefits. However, the market is now experiencing slower growth, marked by a negative compound annual growth rate (CAGR). This is primarily driven by increasing competition from generic alternatives and newer GLP-1 receptor agonists that offer improved efficacy profiles, along with healthcare cost constraints influencing treatment choices.

Although the global prevalence of diabetes continues to rise, creating ongoing demand for effective therapeutic interventions, the market for Victoza is facing pressures from market saturation and pricing competition. The emergence of more cost-effective alternatives and treatment options with enhanced outcomes has affected Victoza’s position. As such, while Victoza remains an important treatment option, its growth is now subdued, and the market is evolving with newer therapies gaining traction in the diabetes management landscape.

Market Dynamics

The global Victoza market is facing a slower growth trajectory, driven by the escalating global prevalence of type 2 diabetes. However, the market’s growth is being tempered by increased competition from generic alternatives and new GLP-1 receptor agonists with better efficacy profiles. While Victoza has proven cardiovascular benefits and is a cornerstone in treatment guidelines, its high cost and patent expiration concerns have limited its expansion, particularly in price-sensitive markets and among uninsured patients.

The market faces significant constraints, including affordability challenges and the introduction of biosimilars that threaten market exclusivity. Moreover, potential side effects, such as gastrointestinal issues and rare cases of pancreatitis, are affecting patient acceptance and physician prescribing patterns. Despite these challenges, there are still opportunities in emerging markets such as Asia Pacific, Latin America, and Africa, where healthcare infrastructure is improving and diabetes awareness is rising. The development of combination therapies and potential expansions into obesity management could further mitigate market slowdown and open new revenue streams for Victoza, though these opportunities may not be sufficient to reverse the overall decline in market growth.

Key Features of the Study

• This report provides in-depth analysis of the global Victoza market, and provides market size (USD Million) and compound annual growth rate (CAGR%) for the forecast period (2025–2032), considering 2024 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global Victoza market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key company covered as a part of this study include Novo Nordisk A/S
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global Victoza market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Victoza market

Market Segmentation

• Indication Insights (Revenue, USD Mn, 2020 - 2032)
• Type 2 Diabetes Mellitus
• Cardiovascular Events
• Strength Insights (Revenue, USD Mn, 2020 - 2032)
• 6 mg
• 2 mg
• 8 mg
• Age Group Insights (Revenue, USD Mn, 2020 - 2032)
• Pediatric
• Adults
• Distribution Channel Insights (Revenue, USD Mn, 2020 - 2032)
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• End User Insights (Revenue, USD Mn, 2020 - 2032)
• Hospitals
• Specialty Clinics
• Outpatient & Primary Care Centers
• Long-Term Care Facilities
• Others (Research & Academic Institutions, etc.)
• Regional Insights (Revenue, USD Mn, 2020 - 2032)
• North America
• U.S.
• Canada
• Latin America
• Brazil
• Argentina
• Mexico
• Rest of Latin America
• Europe
• Germany
• U.K.
• Spain
• France
• Italy
• Russia
• Rest of Europe
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
• GCC Countries
• Israel
• Rest of Middle East
• Africa
• South Africa
• North Africa
• Central Africa
• Key Players Insights
• Novo Nordisk

Show more